Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1 Study of Fast-In-Time Autologous Anti-CD19 Chimeric Antigen Receptor T Cells (FIT-CD19-CAR-T Cells) Infusion for Subjects With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
/ RecruitingEarly Phase 1IIT An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies
/ Not yet recruitingEarly Phase 1IIT An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CD19 Autologous CAR T-cells Produced by Rapid Personalized Manufacture (RPM CD19-mbIL15-CAR-T Cell Infusion) in Patients With Relapsed/Refractory B-cell Malignancies
100 Clinical Results associated with TriArm Therapeutics (Taiwan) Ltd.
0 Patents (Medical) associated with TriArm Therapeutics (Taiwan) Ltd.
100 Deals associated with TriArm Therapeutics (Taiwan) Ltd.
100 Translational Medicine associated with TriArm Therapeutics (Taiwan) Ltd.